Linagliptine Eg (Eurogenerics) Nv (Linagliptin)

Linagliptine Eg acts on the incretin pathway to manage type 2 diabetes mellitus.

• Type 2 diabetes mellitus: improves overall glycaemic control by increasing insulin secretion and reducing glucagon release.
• HbA1c reduction: helps lower glycated haemoglobin levels when added to diet and exercise.
• Fasting plasma glucose: contributes to lower fasting glucose concentrations in patients with inadequate control on other oral agents.

• Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of endogenous incretin hormones such as GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, leading to improved post‑prandial and fasting blood glucose levels.

Adverse reactions reported with linagliptin may vary in frequency and severity.

Common Side Effects

• Nasopharyngitis: mild inflammation of the nasal passages and throat.
• Headache: transient mild to moderate head pain.
• Upper respiratory tract infection: symptoms of cough, sore throat, or congestion.
• Dizziness: occasional sensation of light‑headedness.
• Gastrointestinal discomfort: nausea or loose stools.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain possibly indicating pancreatic inflammation.
• Severe hypersensitivity reactions: including angioedema, Stevens‑Johnson syndrome, or toxic epidermal necrolysis.
• Hepatic injury: elevated liver enzymes or jaundice.
• Severe joint pain: unexplained arthralgia that may require medical evaluation.

Linagliptine Eg should be used with attention to patient‑specific factors and storage conditions.

• Renal impairment: monitor renal function; dose adjustment is not required but caution is advised.
• Hepatic impairment: use with caution in patients with liver disease.
• Cardiovascular disease: observe for any worsening of cardiac status.
• Hypersensitivity: discontinue immediately if signs of severe allergic reaction appear.
• Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Linagliptine Eg may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin effectiveness.
• Co‑administration with insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely)

• Diuretics (especially thiazides): may potentiate hypoglycaemic episodes.
• Antihypertensive agents: additive blood‑pressure lowering effect may occur.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor renal function when combined.